Accelerating Screening & Discovery of Potent Covalent Inhibitors & Degraders with Improved Triaging, Selectivity & Safety for Targeting Hard-to-Drug Targets

Welcome to the Inaugural Covalent Drug Discovery Summit
Tackling “Undruggable” Proteins to Advance Next Generation Covalent Therapeutics

The field of targeted covalent therapeutics is seeing a surge of activity, with both new and established companies investing heavily in the space. The inaugural Covalent Drug Discovery Summit was built alongside industry experts to provide a dedicated forum to tackle associated challenges and advance covalent therapeutics; previously only afforded a small feature in larger ‘small molecule’ conferences.

As the very first meeting solely focused on covalent therapeutics, the 18+ speaker faculty boasted leaders from large pharma, new biotech and academia. This was the summit to meet 80+ covalency experts gathering to solve target selectivity, hit screening, lead optimization, and covalent warhead design to carve out covalency’s niche for targeting the “undruggable” proteome.